Doximity (NYSE:DOCS) stock gained about 16% in the extended trading session yesterday after the company reported an impressive Fiscal fourth-quarter earnings report. The strong performance was driven by higher subscription revenues. Additionally, DOCS provided upbeat revenue and adjusted EBITDA guidance for Fiscal 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Doximity is a digital platform that connects medical professionals, providing networking, telehealth, and information-sharing services.
DOCS’ Q4 Results Snapshot
The company reported adjusted earnings of $0.25 per share, which exceeded analysts’ estimates of $0.20 per share. Furthermore, the reported figure increased by 5% from the prior-year quarter. In the meantime, Q4 revenues of $118.1 million rose by 6% year-over-year, surpassing the Street’s estimates of $116.4 billion. The increase can be attributed to a 9% rise in subscription revenues.
During the quarter, Doximity experienced a 114% net revenue retention rate on a trailing twelve-month basis. Importantly, net revenue retention for the top 20 customers was higher at 122%.
Upbeat Outlook
The company expects its Fiscal 2025 revenues to be between $506 million and $518 million, reflecting a year-over-year growth of 7.7% at the midpoint of the range and above analysts’ forecasts of $520.2 million. Also, Docs expects its adjusted EBITDA to be between $238 million and $250 million.
For the first quarter, Doximity expects revenues to be in the range of $119.5 million to $120.5 million and adjusted EBITDA to be between $238 million and $250 million.
Capital Deployment Activity
Backed by a strong capital position, DOCS announced plans to buy back up to $500 million of the company’s Class A common stock. The repurchase program comes with no expiration date.
Is DOCS a Good Stock to Buy?
Overall, the stock has a Hold consensus rating based on four Hold and one Sell recommendations. After a 15% drop in its share price so far in 2024, analysts’ average price target on Doximity stock of $28.20 implies an upside potential of 18.8% from current levels.
Interestingly, investors interested in DOCS stock could consider following Morgan Stanley (MS) analyst Craig Hettenbach. He is the most accurate and profitable analyst covering the stock (in a one-year timeframe). He boasts an average return of 12.51% per rating and a 90% success rate. Click on the image below to learn more.
